Advertisement

Antidepressants During Breastfeeding

  • Salvatore Gentile
  • Maria Luigia Fusco
Chapter

Abstract

Despite the severe repercussions of maternal depression on the infants’ well-being, women are often reluctant to seek treatment for postpartum depression, with fear of adverse events for the infant playing an important role in such considerations. However, the pharmacological approach to postpartum depression often represents one of the most effective options in a number of clinical conditions. Therefore, the necessity exists to establish the safety of antidepressants in the breastfed infant. The aim of this chapter was to discuss the main criteria that should be considered in the risk/benefit assessment of antidepressant treatment in lactating women. In accordance with the Breastfed Infant-Antidepressant Safety Index classification, sertraline and paroxetine should be considered as first-line medications in women who need to start antidepressant treatment during the postpartum period and wish to continue breastfeeding. Among TCAs, nortriptyline also shows reassuring information; however, primiparous women taking SSRIs are more likely to experience delayed secretory activation. Hence, the decision to start or to continue antidepressant treatment in lactating women should be taken on individual basis, after a careful evaluation of the severity of maternal symptoms and weighing the risk for the mother-infant dyad of exposure to mood symptoms against the risk for the baby of being exposed to antidepressants.

Keywords

Antidepressants Breastfeeding Pregnancy Safety SSRIs Women’s mental health 

References

  1. 1.
    Szucs KA. American Academy of Pediatrics Section on Breastfeeding. J Hum Lact. 2011;27:378–9.PubMedGoogle Scholar
  2. 2.
    Verduci E, Banderali G, Barberi S, et al. Epigenetic effects of human breast milk. Nutrients. 2014;6:1711–24.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Victora CG, Bahl R, Barros AJ, et al. Lancet Breastfeeding Series Group. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet. 2016;387:475–90.Google Scholar
  4. 4.
    Gentile S. SSRIs and mood stabilizers in pregnancy and during breastfeeding. Clinical aspects. Eur Neuropsychopharmacol. 2007b;1:S224.Google Scholar
  5. 5.
    Schirm E, Schwagermann MP, Tobi H, de Jong-van den Berg LT. Drug use during breastfeeding: a survey from the Netherlands. Eur J Clin Nutr. 2004;58:386–90.PubMedGoogle Scholar
  6. 6.
    Gentile S. Untreated maternal depression during pregnancy: short- and long term effects in offspring. A systematic review. Neuroscience. 2017;342:154–66.PubMedGoogle Scholar
  7. 7.
    O’Hara MW, Swain AM. Rates and risk of postpartum depression - a meta-analysis. Int Rev Psychiatry. 1996;8:37–54.Google Scholar
  8. 8.
    Gentile S. Managing antidepressant treatment in pregnancy and puerperium. Careful with that axe, Eugene. Expert Opin Drug Saf. 2015;14:1011–4.PubMedGoogle Scholar
  9. 9.
    Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6:89–98.PubMedGoogle Scholar
  10. 10.
    Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics. 2009;124:e547–56.PubMedGoogle Scholar
  11. 11.
    Kronenfeld N, Berlin M, Shaniv D, Berkovitch M. Use of psychotropic medications in breastfeeding women. Birth Defects Res. 2017;109:957–97.Google Scholar
  12. 12.
    Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015;30:4–20.PubMedGoogle Scholar
  13. 13.
    Gaynes B, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;119:1–8.Google Scholar
  14. 14.
    Gentile S. The role of estrogen therapy in postpartum psychiatric disorders. Un update. CNS Spectr. 2005b;10:944–52.PubMedGoogle Scholar
  15. 15.
    Lanza Di Scalea T, Wisner KT. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52:483–97.PubMedGoogle Scholar
  16. 16.
    Logsdon CM, Wisner KL, Pinto-Foltz MD. The impact of postpartum depression on mothering. J Obstet Gynecol Neonatal Nurs. 2006;35:652–8.PubMedGoogle Scholar
  17. 17.
    Marshall AM, Nommsen-Rivers LA, Hernandez LL, Dewey KJ, Chantry CJ, Gregerson KA, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. Clin Endocrinol Metab. 2010;95:837–46.Google Scholar
  18. 18.
    O’Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000;57:1039–45.PubMedGoogle Scholar
  19. 19.
    Pearlstein TB, Zlotnick C, Battle CL, et al. Patient choice of treatment for postpartum depression: a pilot study. Arch Womens Ment Health. 2006;9:303–8.PubMedGoogle Scholar
  20. 20.
    Pilowsky DJ, Wickramaratne PJ, Rush AJ, et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006;67:126–36.PubMedGoogle Scholar
  21. 21.
    The Breastfeeding Network. Antidepressants and breastfeeding, May 2017. Paisley: The Breastfeeding Network; 2017. https://breastfeedingnetwork.org.uk/wp-content/dibm/antidepressants%20and%20breastfeeding.pdf. Accessed on 18 Oct 2017.Google Scholar
  22. 22.
    Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005a;28:137–52.PubMedGoogle Scholar
  23. 23.
    Berle JØ, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry. 2004;65:1228–34.PubMedGoogle Scholar
  24. 24.
    Brent NB, Wisner LK. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr. 1998;37:41–4.Google Scholar
  25. 25.
    Burch KJ, Wells G. Fluoxetine/Norfluoxetine concentrations in human milk. Pediatrics. 1992;89:676–7.PubMedGoogle Scholar
  26. 26.
    Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics. 1999;104:e61.PubMedGoogle Scholar
  27. 27.
    Epperson CN, Jatlow PI, Czarkowski MA, Anderson GM. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breast-feeding mother-infant pairs. Pediatrics. 2003;112:e425–9.PubMedGoogle Scholar
  28. 28.
    Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr. 2001;40:681–4.Google Scholar
  29. 29.
    Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73:330–7.PubMedGoogle Scholar
  30. 30.
    Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breastmilk. Biol Psychiatry. 2001a;50:775–82.PubMedGoogle Scholar
  31. 31.
    Kim J, Misri S, Riggs KW, et al. Stereoselective excretion of fluoxetine and norfluoxetine in breastmilk and neonatal exposure. Presented at the American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.Google Scholar
  32. 32.
    Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48:521–7.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry. 1990;51:169.PubMedGoogle Scholar
  34. 34.
    Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32:1253–5.PubMedGoogle Scholar
  35. 35.
    Moretti ME, Sharma A, Bar-Oz B, Koren G. Fluoxetine and its effects on the nursing infant: a prospective cohort study. Clin Pharmacol Ther. 1989;65:141.Google Scholar
  36. 36.
    Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics. 2005;115:411–25.PubMedGoogle Scholar
  37. 37.
    Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol. 1996;36:42–7.PubMedGoogle Scholar
  38. 38.
    Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161:1066–78.PubMedGoogle Scholar
  39. 39.
    Yoshida K, Smith B, Craggs M, Channi KR. Fluoxetine in breast-milk and developmental outcomes if breast-fed infants. Br J Psychiatry. 1998;172:175–9.PubMedGoogle Scholar
  40. 40.
    Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimating of nursing infant daily dose fluoxetine through breast milk. Biol Psychiatry. 2002;52:446–51.PubMedGoogle Scholar
  41. 41.
    Kim J, Riggs KW, Misri S, Kent N, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006;61:155–63.PubMedGoogle Scholar
  42. 42.
    Alehan F, Saygi S, Tarcan A, et al. Prolonged neonatal complications after in utero exposure to fluoxetine. J Matern Fetal Neonatal Med. 2008;21:921–3.PubMedGoogle Scholar
  43. 43.
    Morris R, Matthes J. Serotonin syndrome in a breast-fed neonate. BMJ Case Rep. 2015;2015:pii: bcr2015209418. https://doi.org/10.1136/bcr-2015-209418.CrossRefGoogle Scholar
  44. 44.
    Gentile S. On categorizing gestational birth, and neonatal complications following late in utero exposure to antidepressants. The prenatal antidepressant exposure syndrome. CNS Spectr. 2010;15:167–85.PubMedGoogle Scholar
  45. 45.
    Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health. 2006;9:158–9.PubMedGoogle Scholar
  46. 46.
    Hagg S, Granberg K, Carleborg L. Excretion of fluvoxamine into breast milk. Br J Pharmacol. 2000;49:286–8.Google Scholar
  47. 47.
    Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry. 2001b;179:163–6.PubMedGoogle Scholar
  48. 48.
    Kristensen JH, Hackett P, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact. 2002;18:139–43.PubMedGoogle Scholar
  49. 49.
    Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2001;62:111–3.PubMedGoogle Scholar
  50. 50.
    Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol. 1991;31:209.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Yoshida K, Smith B, Kumar RC. Fluvoxamine in breast-milk and infant development. Br J Pharmacol. 1997a;44:210–1.Google Scholar
  52. 52.
    Uguz F. Gastrointestinal side effects in the baby of a breastfeeding woman treated with low-dose fluvoxamine. J Hum Lact. 2015;3:1–3.Google Scholar
  53. 53.
    Gentile S. Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index. Drug Saf. 2007a;30:107–21.PubMedGoogle Scholar
  54. 54.
    Öhman R, Hägg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry. 1999;60:519–23.PubMedGoogle Scholar
  55. 55.
    Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol. 1999;48:142–7.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Hendrick V, Stowe ZN, Altshuler L, Hostetter A, Fukuchi A. Paroxetine use during breastfeeding. J Clin Psychopharmacol. 2000;20:587–9.PubMedGoogle Scholar
  57. 57.
    Merlob P, Stahl B, Sulkes J. Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel. Eur J Pediatr. 2004;163:135–9.PubMedGoogle Scholar
  58. 58.
    Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry. 2000;61:828–32.PubMedGoogle Scholar
  59. 59.
    Nordeng H, Bergsholm YK, Boiler E, Spigset O. The transfer of serotonin reuptake inhibitors to human milk. Tidsskr Nor Laegeforen. 2001;121:199–203.PubMedGoogle Scholar
  60. 60.
    Spigset O, Carleborg L, Noström Å, Sandlund M. Paroxetine level in breast milk. J Clin Psychiatry. 1996;57:39.PubMedGoogle Scholar
  61. 61.
    Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. Am J Psychiatry. 2000;157:185–9.PubMedGoogle Scholar
  62. 62.
    Uguz F, Arpaci N. Short-term safety of paroxetine and sertraline in breastfed infants. A retrospective cohort study from a University hospital. Breastfed Med. 2016;11:487–9.Google Scholar
  63. 63.
    Wisner LK, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry. 1998;55:690–2.Google Scholar
  64. 64.
    Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence. Br J Psychiatry. 1995;167:412–3.PubMedGoogle Scholar
  65. 65.
    Altshuler LL, Burt VK, McMullen M, Hendrick V. Breastfeeding and sertraline: a 24-hours analysis. J Clin Psychiatry. 1995;56:243–5.PubMedGoogle Scholar
  66. 66.
    Dodd S. Sertraline analysis in the plasma of breastfed infants. Aust N Z J Psychiatry. 2001;33:545–6.Google Scholar
  67. 67.
    Dodd S, Stocky A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol Clin Exp. 2000a;15:261–4.Google Scholar
  68. 68.
    Epperson CN, Anderson GM, McDougle CJ. Sertraline and breastfeeding. New Engl J Med. 1997;336:1189–90.PubMedGoogle Scholar
  69. 69.
    Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol. 1998;45:453–7.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Mammen OK, Perel JM, Rudolph G, Foglia JP, Wheeler SB. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry. 1997a;58:100–3.PubMedGoogle Scholar
  71. 71.
    Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry. 1997;154:1255–60.PubMedGoogle Scholar
  72. 72.
    Winn SS, Drawer PO, Stowe ZN, et al. Sertraline in breast milk and nursing infants. Proc 148th Annual Meeting Psychiatric Association, Miami, FL, 1995, p.73, Abstract #NR72.Google Scholar
  73. 73.
    Müller MJ, Preuß C, Paul T, Streit F, Bandhorst G, Seeliger S. Serotonergic overstimulation in a preterm infant after sertraline intake via breastmilk. Breastfeed Med. 2013;8:327–9.PubMedGoogle Scholar
  74. 74.
    Morin C, Chevalier I. Severe hypernatremic dehydration and lower limb gangrene in an infant exposed to lamotrigine, aripiprazole, and sertraline in breast milk. Breastfeed Med. 2017;12:377–80.PubMedGoogle Scholar
  75. 75.
    Holland D. An observation of the effect of sertraline on breast milk supply. Aust N Z J Psychiatry. 2000;34:1032.PubMedGoogle Scholar
  76. 76.
    Franssen EJF, Meijs V, Ettaher F, Valerio PG, Keessen M, Lameijer W. Citalopram serum and milk levels in mother and infant during lactation. Ther Drug Monitor. 2006;28:2–4.Google Scholar
  77. 77.
    Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184–91.PubMedGoogle Scholar
  78. 78.
    Jensen PR, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monitor. 1997;8:236–9.Google Scholar
  79. 79.
    Lee A, Woo J, Ito S. frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol. 2004;190:218–21.PubMedGoogle Scholar
  80. 80.
    Öhman I, Norstedt Wikner B, Vitols S. Citalopram and metabolite levels in plasma and breast milk in two nursing women [Abstract n. 581]. Eur J Clin Pharmacol. 1997;52(Suppl):A179.Google Scholar
  81. 81.
    Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and desmethylcitalopram in human milk: distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol. 2000;50:263–8.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry. 2000;47:164–5.PubMedGoogle Scholar
  83. 83.
    Spigset O, Carleborg L, Öhman R, Nosrtröm Å. Excretion of citalopram in breast milk. Br J Psychopharmacol. 1997;44:295–8.Google Scholar
  84. 84.
    Rampono J, Hackett LP, Kristensen JH, Kohan R, Page-Sharp M, Ilett KF. Transfer of escitalopram its active metabolite desmethylescitalopram into breastmilk. Br J Clin Pharmacol. 2006;62:316–22.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Ilett KF, Hackett PC, Kristensen JH, Rampono J, Rolland K. Estimation of infant dose and assessment of breastfeeding safety for escitalopram use in postnatal depression. Ther Drug Monitor. 2005;27:248.Google Scholar
  86. 86.
    Castberg I, Spigset O. Excretion of escitalopram in breast milk. J Clin Psychopharmacol. 2006;26:536–8.PubMedGoogle Scholar
  87. 87.
    Bellantuono C, Bozzi F, Orsolini L, Catena-Dell’Osso M. The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol. 2012;27:534–9.PubMedGoogle Scholar
  88. 88.
    Bellantuono C, Vargas M, Mandarelli G, Nardi B, Martini MG. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol. 2015;30:143–51.PubMedGoogle Scholar
  89. 89.
    Bennet PN. Use of the monographs on drugs. In: Bennet PN, editor. Drug and human lactation. 2nd ed. Amsterdam: Elsevier; 1996. p. 67–74.Google Scholar
  90. 90.
    Hendrick V, Altshuler L, Wertheimer A, Dunn WA. Venlafaxine and breastfeeding. Am J Psychiatry. 2001c;158:2089–90.PubMedGoogle Scholar
  91. 91.
    Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol. 2002;53:17–22.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Ilett KF, Hackett LP, Dushi LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine metabolite in human milk. Br J Clin Pharmacol. 1998;45:459–62.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S. Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010;32:704–7.PubMedGoogle Scholar
  94. 94.
    Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry. 2009;70:1304–10.PubMedGoogle Scholar
  95. 95.
    Rampono J, Teoh S, Hackett LP, Kohan R, Ilett KF. Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health. 2011;14:49–53.PubMedGoogle Scholar
  96. 96.
    Koren G, Moretti M, Kapur B. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome? J Obstet Gynaecol Can. 2006;28:299–31.PubMedGoogle Scholar
  97. 97.
    Lobo ED, Loghin C, Mary Pat Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008;47:103–9.PubMedGoogle Scholar
  98. 98.
    Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014;13:207–25.PubMedGoogle Scholar
  99. 99.
    Rasmussen F. The mechanism of drug secretion into milk. In: Brodie BB, Gillette JR, editors. Concepts in biochemical pharmacology, vol. 1. New York, NY: Springer; 1973. p. 231–45.Google Scholar
  100. 100.
    Gentile S, Rossi A, Bellantuono C. SSRIs during breastfeeding: spotlight on milk-to-plasma ratio. Arch Womens Ment Health. 2007;10:39–51.PubMedGoogle Scholar
  101. 101.
    Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889–95.PubMedGoogle Scholar
  102. 102.
    Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics. 1999;104:e11.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry. 1979;136:451–2.PubMedGoogle Scholar
  104. 104.
    Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord. 1997b;43:225–37.PubMedGoogle Scholar
  105. 105.
    Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med. 1991;21:157–71.PubMedGoogle Scholar
  106. 106.
    Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and infant’s serum. Am J Psychiatry. 1896;143:597–600.Google Scholar
  107. 107.
    Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant’s serum. Am J Psychiatry. 1980;137:855–6.PubMedGoogle Scholar
  108. 108.
    Breyer-Pfaff U, Karl N, Entermann A, et al. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry. 1995;152:812–3.PubMedGoogle Scholar
  109. 109.
    Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology (Berl). 1982;76:94–5.Google Scholar
  110. 110.
    Erickson SH, Smith GH, Heidrich F. Tryciclics and breastfeeding. Am J Psychiatry. 1979;136:1483.PubMedGoogle Scholar
  111. 111.
    Pittard WB III, O’Neal W Jr. Amitriptyline excretion in human milk. J Clin Psychopharmacol. 1986;6:383–4.PubMedGoogle Scholar
  112. 112.
    Mammen O, Perel JM, Wheeler S. Antidepressants and breastfeeding. Am J Psychiatry. 1997b;154:1174.PubMedGoogle Scholar
  113. 113.
    Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast difference in two patients. Eur J Pharmacol. 1988;35:217–20.Google Scholar
  114. 114.
    Wisner KL, Perel JM, Findling RL, Hinnes RL. Nortriptyline and its hydroxy metabolites in breastfeeding mothers and newborns. Psychopharmacol Bull. 1997;33:249–51.PubMedGoogle Scholar
  115. 115.
    Wisner KL, Perel JM. Nortriptyline treatment of breastfeeding women. Am J Psychiatry. 1996;153:295.PubMedGoogle Scholar
  116. 116.
    Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry. 1991;148:1234–6.PubMedGoogle Scholar
  117. 117.
    Schimmell MS, Zylber Katz E, Shaag Y, Pastuszac A, Koren G. Toxic neonatal effects following maternal clomipramine therapy. Clin Toxicol. 1991;29:479–84.Google Scholar
  118. 118.
    Eggermont E, Raveschot J, Deneve V, et al. The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life. Acta Paediatr Belg. 1972;26:197–204.PubMedGoogle Scholar
  119. 119.
    Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry. 1995;56:17–20.PubMedGoogle Scholar
  120. 120.
    Buist A, Norman T, Dennerstein L. Plasma and breast milk concentrations of dothiepin and northiaden in lactating women. Hum Psychopharmacol. 1993;8:29–33.Google Scholar
  121. 121.
    Ilett KF, Lebedevs TH, Wojnar-Horton RE, et al. The excretion of dothiepin and its primary metabolites in breast milk. Br J Clin Pharmacol. 1992;33:635–9.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Frey OR, Scheidt P, von Brenndorff AI. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacother. 1999;8:690–3.Google Scholar
  123. 123.
    Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet. 1985;11:1124.Google Scholar
  124. 124.
    Kemp J, Ilett KF, Booth J, et al. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol. 1985;20:497–9.PubMedPubMedCentralGoogle Scholar
  125. 125.
    Baab SW, Peindl K, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry. 2002;63:910–1.PubMedGoogle Scholar
  126. 126.
    Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann Pharmacother. 1993;27:431–3.PubMedGoogle Scholar
  127. 127.
    Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of possible infant seizures. J Clin Psychiatry. 2004;65:881–2.PubMedGoogle Scholar
  128. 128.
    Davis MF, Miller HS, Nolan PE. Bupropion levels in breast milk for 4 mother-infant pairs: more answers to lingering question. J Clin Psychiatry. 2009;70:297–8.PubMedGoogle Scholar
  129. 129.
    Haas JS, Kaplan C, Barenboim D, Jacob P 3rd, Benowitz NL. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control. 2004;13:52–6.PubMedPubMedCentralGoogle Scholar
  130. 130.
    (No authors listed). Bupropion: seizures in an infant exposed through breast-feeding. Prescribe Int. 2005;14:144.Google Scholar
  131. 131.
    Neuman G, Colantonio D, Delaney S, Szynkaruk M, Ito S. Bupropion and escitalopram during lactation. Ann Pharmacother. 2014;48:928–31.PubMedGoogle Scholar
  132. 132.
    Dodd S, Maguire KP, Burrows GD, Norman TR. Nefazodone in the breast milk of nursing mothers: a report of two patients. J Clin Psychopharmacol. 2000b;20:717–8.PubMedGoogle Scholar
  133. 133.
    Yapp P, Ilett KF, Kristensen JH, Hackett PL, Paech MJ, Rampono J. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. Ann Pharmacother. 2000;34:1269–72.PubMedGoogle Scholar
  134. 134.
    Aichhorn W, Whitworth AB, Weiss U, Stuppaek C. Mirtazapine and breast-feeding. Am J Psychiatry. 2004;161:2325.PubMedGoogle Scholar
  135. 135.
    Kristensen JH, Ilett KF, Rampono J, Kohan R, Hackett LP. Transfer of antidepressant mirtazapine into breastmilk. Br J Pharmacol. 2007;63:322–7.Google Scholar
  136. 136.
    Klier CM, Mossaheb N, Lee A, Zernig G. Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Psychiatry. 2007;164:348–9.PubMedGoogle Scholar
  137. 137.
    Tonn P, Reuter S, Hiemke C, Dahmen N. High mirtazapine plasma levels in infant after breast feeding. Case report and review of the literature. J Clin Psychopharmacol. 2009;29:191–2.PubMedGoogle Scholar
  138. 138.
    Smit M, Wennink HJMB, Heres MMHB, Dolman KKM, Honig A. Mirtazapine in pregnancy and lactation. Data from a case series. J Clin Psychopharmacol. 2015;35:163–7.PubMedGoogle Scholar
  139. 139.
    Hackett PL, Ilett KF, Rampono J, Kristensen JH, Kohan R. Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infants. Eur J Pharmacol. 2006;62:633–8.Google Scholar
  140. 140.
    EMEA. Vortioxetine. ANNEX I. Summary of Product characteristics. London: EMEA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf. Accessed on 17 Oct 2017.
  141. 141.
    Hale TW, Kendall-Tackett K, Cong Z, Votta R, McCurdy F. Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding. Breastfeed Med. 2010;5:1–6.Google Scholar
  142. 142.
    Letourneau NL, Dennis CL, Cosic N, Linder J. The effect of perinatal depression treatment for mothers on parenting and child development: a systematic review. Depress Anxiety. 2017;34:928. https://doi.org/10.1002/da.22687.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Salvatore Gentile
    • 1
  • Maria Luigia Fusco
    • 2
    • 3
  1. 1.Department of Mental Health, ASL SalernoMental Health Center Cava de’ Tirreni - Vietri sul MareCava de’ TirreniItaly
  2. 2.Developmental PsychologistMental Health InstituteNaplesItaly
  3. 3.Developmental PsychologyPost-graduate School of Psychotherapy (SIPGI)NaplesItaly

Personalised recommendations